SLC5A2 and heart failure: Few clinical trials have investigated the utilization of SGLT-2 inhibitors and GLP-1 receptor agonists in HFpEF; clinical outcomes included various parameters, including heart failure hospitalizations, symptom burden, as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, and functional capacity, as measured by a 6-minute walk test distance [7].